Cerebrospinal fluid pleocytosis is associated with HIV-1 neuroinvasion during acute infection.

Authors:
Chan P; Moreland S; Sacdalan C; Kroon E; Colby D and 10 more

Journal:
AIDS

Publication Year: 2023

DOI:
10.1097/QAD.0000000000003777

PMCID:
PMC10842649

PMID:
37916464

Journal Information

Full Title: AIDS

Abbreviation: AIDS

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Acquired Immunodeficiency Syndrome

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of interest There are no conflicts of interest."

Evidence found in paper:

"We thank the RV254/SEARCH 010 participants, the International NeuroHIV Cure Consortium that is funded by the National Institute of Mental Health, and staff from the Thai Red Cross AIDS Research Centre, Institute of HIV Research and Innovation (IHRI), Chulalongkorn University, and Armed Forces Research Institute of Medical Sciences for their valuable contributions to this study. We are grateful to the Thai Government Pharmaceutical Organization, ViiV Healthcare, Gilead Sciences, and Merck for providing the antiretroviral medications for this cohort. Financial support: the RV254/SEARCH 010 study is supported by cooperative agreements (WW81XWH18–2–0040) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the US Department of Defense (DOD) and by an intramural grant from the Thai Red Cross AIDS Research Centre. This research was funded, in part, by the US NIAID (AAI20052001), The National Institute of Mental Health (NIMH) (R01MH106466), National Institute of Neurological Disorders and Stroke (NINDS) (R01NS084911), and NIMH support of the International NeuroHIV Cure Consortium. Antiretroviral therapy for RV254/SEARCH 010 participants was supported by the Thai Government Pharmaceutical Organization, Gilead Sciences, Merck, and ViiV Healthcare."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025